Elsevier

Brachytherapy

Volume 5, Issue 2, April–June 2006, Pages 122-126
Brachytherapy

PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure: A study of 295 patients with a minimum 3-year followup

https://doi.org/10.1016/j.brachy.2006.02.003Get rights and content

Abstract

Purpose

To assess the frequency and features of the PSA bounce phenomenon in a series of patients treated with permanent implant brachytherapy for prostate cancer, and to evaluate the percentage of cases in which this bounce could have mimicked a biochemical relapse according to the American Society for Therapeutic Radiology and Oncology consensus criteria.

Methods and materials

From January 1999 to December 2001, 295 patients were treated with a permanent prostate implantation (real-time technique, with free 125I seeds) by the Paris Institut Curie/Hospital Cochin/Hospital Necker Paris group. Duration of followup is 40.3 months (9–66 months). PSA level was reported at intervals not exceeding 6 months. Bounce was defined by temporary elevation in PSA level, followed by a spontaneous decrease.

Results

In our series, 161 patients (55%) showed a transitory PSA increase (bounce) of at least 0.1 ng/mL; 145 patients (49%) a bounce of 0.2 ng/mL; 93 patients (32%) a bounce of 0.4 ng/mL; and 43 patients (15%) a bounce of at least 1 ng/mL. Mean PSA bounce was 0.8 ng/mL (0.1–4.1), and mean time to bounce was 19 months. Thirty-two patients (11% of total) presented three successive PSA increases, and therefore were to be considered as experiencing a biochemical relapse according to the American Society for Therapeutic Radiology and Oncology (ASTRO) consensus criteria. Among those 32 patients, 18 (56%) subsequently showed, without any treatment, a complete normalization of their PSA. In multivariate analysis, age <70 (p < 0.0001) and D90 > 200 Gy (p < 0.003) were identified as independent factors for a PSA bounce of at least 0.4 ng/mL.

Conclusions

The observed rate of 32% of patients showing a PSA bounce of at least 0.4 ng/mL in our series is in good agreement with what has been previously reported in the literature. Among 32 patients fulfilling the classical ASTRO criteria for a biochemical relapse, 18 (56%) subsequently showed a spontaneous PSA decrease, questioning the ASTRO consensus for the biochemical followup of patients undergoing permanent implant prostate brachytherapy.

Introduction

After radical prostatectomy, prostate-specific antigen (PSA) drops rapidly (1) and levels should remain undetectable. These levels fall to low but usually detectable levels after prostate brachytherapy (2).

A commonly used definition of biochemical failure after radiation was developed by the ASTRO 8 years ago at a consensus conference. The criteria for failure are three consecutive increases in PSA, with the date of failure defined as the midpoint between postirradiation nadir PSA and the first of the three consecutive rises (3).

Although elevated PSA after treatment can be a sign of disease recurrence, it has also been reported that patients treated with prostate brachytherapy (and external beam radiotherapy) can have a temporary PSA elevation without evidence of disease recurrence. This phenomenon has been termed PSA bounce, bouncing or spike [4], [5], [6], [7], [8].

PSA bounces often result in patient and physician anxiety, as well as subsequent unnecessary therapeutic interventions. In particular, because patients are often treated with hormonal therapy based on postimplantation PSA increases, a benign PSA “bounce” should be ruled out before a therapy with possible side effects is initiated [9], [10].

As permanent prostate brachytherapy is being more widely used (11), PSA bounce will assume more importance for both patients and physicians.

Section snippets

Patients

Between January 1999 and December 2001, 295 prostate cancer patients were treated with 125I seed implantation by the Paris Institut Curie/Hospital Cochin/Hospital Necker Group. Patients were selected according to criteria slightly different from those recommended by the American Brachytherapy Society [12], [13], [14]. Patients were considered eligible for such a treatment if they had clinical stage T1–T2 cancer, Gleason ≤7 (3 + 4), and PSA level ≤15 ng/mL. Systematic endorectal MRI revealed no

Results

The median followup of the entire cohort of 295 patients was 40.3 months (range 9–66).

The majority of patients have a minimum of 3 years followup (230/295, i.e., 78% of patients), with only four patients with less than 24 months of followup (one is lost for followup and three are deceased).

D90 was superior to 145 Gy in almost all patients (294/295), with 77 patients (26.1%) with a D90 superior to 200 Gy, on the CT-based dosimetry obtained on day 60 after prostate implantation. One hundred

Discussion

No definition of PSA failure has, as yet, proved to be a perfect surrogate for clinical progression or survival. Nadir PSA is a strong prognostic factor, but no absolute level could be identified as a valid cutoff for separating successful and unsuccessful treatments.

The recognition of a PSA bounce seems to be important in treating patients who underwent brachytherapy for prostate cancer. Unlike radical prostatectomy, for which the PSA level should fall to undetectable levels, brachytherapy

Conclusion

Posttreatment PSA bouncing occurs frequently in men treated with permanent implant brachytherapy for prostate cancer: 32% of the patients in the present series of 295 cases showed a transitory PSA increase of at least 0.4 ng/mL. The median time to bounce after brachytherapy was 19 months, with almost all cases (95%) occurring within the first 3 years after implantation.

In multivariate analysis, age <70 and D90 >200 Gy were identified as independent factors for a PSA bouncing of at least 0.4 ng/mL,

Acknowledgment

We are grateful to Dr. Wendla Citron for fruitful discussion and translation assistance.

References (29)

Cited by (54)

  • Manual vs. automated implantation of seeds in prostate brachytherapy: Oncologic results from a single-center study

    2018, Brachytherapy
    Citation Excerpt :

    PSA bounce, defined as an increase of ≥0.2 ng/mL followed by a decrease without any treatment, occurred in 128 patients (36.6%). This rate is similar to other reported series (30, 31). Bounce occurred with a median delay of 16.1 months (14.8–18.6) after brachytherapy which is in agreement with other reported series (6, 27, 32) except for the Leduc (30) (in a non-Caucasian population) and Engeler series (33), wherein both studies reported a median occurrence delay of 12 months after brachytherapy.

  • Curative brachytherapy for prostate cancer in African-Caribbean patients: A retrospective analysis of 370 consecutive cases

    2017, Brachytherapy
    Citation Excerpt :

    All brachytherapists were trained and supervised by an experimented physician from the service who earlier reported an extensive experience (21). Refresher courses were conducted in collaboration with the Center Oscar Lambret, Lille, France, and with the Institut Curie, Paris, France, under the guidance of Jean-Marc Cosset (Expert brachytherapist in Institut Curie, France) (22). Thirty patients between 2005 and 2007 received linked seeds 125I brachytherapy (IMC7000 RAPID Strand seed, Amersham, ONCURA).

View all citing articles on Scopus
View full text